Previously, bone marrow transplantation (BMT) or hematopoietic stem cell transplantation (HSCT) in patients with chronic granulomatous disease was accompanied by a fairly high failure rate. Moreover, this was often associated with the unsatisfactory pre-transplant status of patients, in particular, with fungal infection, which, as is known, along with GVHD, occupies one of the leading places in the structure of post-transplant mortality.